Hørsholm,
This comprehensive report analyses recent updates to the company's platform technology and key assets, with a deep dive into the HER2+ breast cancer vaccine candidate ES2B-C001. It provides an assessment of the company's cash position and an updated sum-of-the-parts valuation. Pareto revised its price target to
Certified Adviser
For further information about ExpreS2ion
Bent U. Frandsen, CEO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2(TM), for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2(TM), includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with
https://news.cision.com/expres2ion-biotechnologies/r/pareto-securities-publishes-research-report,c3887341
https://mb.cision.com/Main/14402/3887341/2471248.pdf
(c) 2023 Cision. All rights reserved., source